Real-World Treatment Patterns and Effectiveness of Anti-EGFR- and Anti-VEGF-based Therapies in Left-sided RAS Wild-Type Metastatic Colorectal Cancer

Brief summary (registry, in English)

The aim of this study is to learn how doctors treat a type of metastatic colorectal cancer in everyday medical practice. The study focuses on patients whose cancer started on the left side of the colon and does not have specific gene changes called RAS mutations (this is known as RAS wild-type disease). It will assess effectiveness of two common types of targeted treatments: anti-EGFR medicines, which block signals that help cancer cells grow, and anti-VEGF medicines, which block the growth of blood vessels that supply tumors. This is a real-world study, not a clinical study. This means that researchers will look at what happens when patients receive the treatments prescribed by their own doctor as part of their usual healthcare treatment. In this study, researchers will use information derived and de-identified from cancer clinics across the United States (from the Flatiron Health Analytic Database).

What you commit to

• Study type: Observational
• Planned participants: 1
• From 30 Oct 2026 to the primary completion date, 30 Nov 2027
• No sites listed in no country
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov